1. University of Kragujevac Digital Archive
  2. University of Kragujevac
  3. Faculty of Medical Sciences, Kragujevac
Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/15053
Full metadata record
DC FieldValueLanguage
dc.rights.licenserestrictedAccess-
dc.contributor.authorTodorovic Z.-
dc.contributor.authorJakovcev-Todorovic D.-
dc.contributor.authorGrbovic-Markovic V.-
dc.contributor.authorLadjevac N.-
dc.contributor.authorZdravković N.-
dc.contributor.authorDjurdjevic, Predrag-
dc.contributor.authorArsenijevic, Nebojsa-
dc.contributor.authorMilovanovic, Marija-
dc.contributor.authorArsenijevic A.-
dc.contributor.authorMilovanovic, Jelena-
dc.date.accessioned2022-09-13T11:49:43Z-
dc.date.available2022-09-13T11:49:43Z-
dc.date.issued2022-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/15053-
dc.description.abstractChimeric antigen receptor T (CAR T) cell therapy achieved remarkable success in B-cell leukemia and lymphoma which led to its incorporation in treatment protocols for these diseases. CAR T cell therapy for chronic lymphocytic leukemia (CLL) patients showed less success compared to other malignant tumors. In this review, we discuss the published results regarding CAR T cell therapy of CLL, possible mechanisms of failures and expected developments.-
dc.rightsinfo:eu-repo/semantics/restrictedAccess-
dc.sourceCurrent Oncology-
dc.titleCAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings-
dc.typereview-
dc.identifier.doi10.3390/curroncol29050293-
dc.identifier.scopus2-s2.0-85130550535-
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

441

Downloads(s)

10

Files in This Item:
File Description SizeFormat 
PaperMissing.pdf
  Restricted Access		29.85 kBAdobe PDFThumbnail
View/Open
Show simple item record


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.